Screening of Carbamazepine-Ibuprofen Co-Crystal Formation Using Non-Stoichiometric and Stoichiometric Methods

Abstract:

The paper presents the co-crystal screening study of carbamazepine (CBZ) and ibuprofen (IBU) as a co-crystal former (CCF) using non-stoichiometric (solid addition of CBZ to saturated solution of co-crystal former (CCF) and stoichiometric (1:1 mol of CBZ and CCF) methods. In the non-stoichiometric method, CBZ-IBU co-crystal was prepared in various solvents and left to equilibrate in three conditions; stagnant, manually agitated and shaking in 72 hours whereas in the stoichiometric method, evaporation, solvent drop grinding and dry grinding were used. The crystals produced from the screening process were characterized using differential scanning calorimetry (DSC) and optical microscopy. The co-crystal of CBZ-IBU was found to have successfully formed via the non-stoichiometric method in formic acid. DSC analysis revealed that the remaining crystals produced were either CBZ or IBU as indicated by their respective melting point.

• Periodical: Advanced Materials Research (Volume 1113)
• Pages: 417-421
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.1113.417
• Online since: July 2015
• Authors: Syarifah Abd Rahim*, Nurul Aini Rosli, Siti Salasiah Mohd Khalid
• Keywords: Carbamazepine, Co-Crystal, Co-Crystal Former, Co-Crystal Screening, Ibuprofen

References

[1] S.R. Vippagunta, H.G. Brittain, D.J.W. Grant, Crystalline solids, Adv. Drug Deliv. Rev. 48 (2001) 3–26.

[2] N. Shan, M.J. Zaworotko, The role of cocrystals in pharmaceutical science, Drug Discov. Today 13 (2008) 440–446.

DOI: 10.1016/j.drudis.2008.03.004

[3] N. Qiao, M. Li, W. Schlindwein , N. Malek, A. Davies, G. Trappitt, Pharmaceutical cocrystals: An overview, Int. J. Pharm. 419 (2011) 1-11.

DOI: 10.1016/j.ijpharm.2011.07.037

[4] I. Miroshynk, S. Mirza, N. Sandler, Pharmaceutical co-crystals - an opportunity for drug product enhancement, Expert Opin. Drug Deliv. 6 (2009) 333–341.

DOI: 10.1517/17425240902828304

[5] S.L. Morissette, O. Almarsson, M.L. Peterson, J.F. Remenar, M.J. Read, A.V. Lemmo, S. Ellis, M.J. Cima, C.R. Gardner, High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids, Adv. Drug Deliv. Rev. 56 (2004).

DOI: 10.1016/j.addr.2003.10.020

[6] M.A. Mohammad , A. Alhalaweh, S.P. Velaga, Hansen solubility parameter as a tool to predict cocrystal formation, Int. J. Pharm. 407 (2011) 63–71.

DOI: 10.1016/j.ijpharm.2011.01.030

[7] B.S. Sekhon, Nutraceutical cocrystals: an overview, RGUHS J. Pharm. Sci. 2 (2012) 16-25.

[8] J. Haleblian, W. McCrone, Pharmaceutical applications of polymorphism, J. Pharm. Sci. 58 (1969) 911–929.

DOI: 10.1002/jps.2600580802

[9] S. Abd Rahim, R. B. Hammond, A. Y. Sheikh and K. J. Roberts, A comparative assessment of the influence of different crystallization screening methodologies on the solid forms of carbamazepine co-crystals, CrystEngComm. 15 (2013) 3862-3873.

DOI: 10.1039/c3ce26878k

[10] A.L. Grzesiak, M. Lang, K. Kim K, A.J. Matzger, Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I, J. Pharm. Sci. 92 (2003) 2260-2271.

DOI: 10.1002/jps.10455

[11] H. Cano, N. Gabas, J.P. Canselier, Experimental study on the ibuprofen crystal growth morphology in solution, J. Cryst. Growth 224 (2001) 335–341.

DOI: 10.1016/s0022-0248(01)00969-1

[12] S.K. Dwivedi, S. Sattari, F. Jamali, A.G. Mitchell, Ibuprofen racemate and enantiomers: phase diagram, solubility and thermodynamic studies, Int. J. Pharm. 87 (1992) 95–104.

DOI: 10.1016/0378-5173(92)90232-q

[13] R. Mahalaxmi, Ravikumar, S. Pandey, A. Shirwaikar, A. Shirwaikar, Effect of recrystallization on size, shape, polymorph and dissolution of carbamazepine, Int. J. PharmTech. Res. 1 (2009) 725-732.

[14] C. Acquah, A.T. Karunanithi, M. Cagnetta, L.E.K. Achenie, S.L. Suib, Linear models for prediction of ibuprofen crystal morphology based on hydrogen bonding propensities, Fluid Phase Equilibria 277 (2009) 73–80.

DOI: 10.1016/j.fluid.2008.11.015

[15] M.A. O'Mahony, A. Maher, D.M. Croker, Å.C. Rasmuson, B.K. Hodnett, Examining solution and solid state composition for the solution-mediated polymorphic transformation of carbamazepine and piracetam, Cryst. Growth Des. 12 (2012) 1925−(1932).

DOI: 10.1021/cg201665z

[16] R. Elqidra, N. Unlu, Y. Capan, G. Sahin, T. Dalkora, A.A. Hincal, Effect of polymorphism on in vitro-in vivo properties of carbamazepine conventional tablets. J. Drug Del. Sci. Tech, 14 (2004) 147-153.

DOI: 10.1016/s1773-2247(04)50027-8

[17] N. Rasenack, B.W. Muller, Properties of ibuprofen crsytallized under various conditions: a comparative study, Drug Dev. Ind. Pharm. 28 (2002) 1077-1089.